Efficacy of Pirfenidone Vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a Analysis

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Jul 5

PMID 35783648

Authors

Maria Molina-Molina

Michael Kreuter

Vincent Cottin

Tamera J Corte

Frank Gilberg

Klaus-Uwe Kirchgaessler

Judit Axmann

Toby M Maher

Affiliations

Soon will be listed here.

Abstract

Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT03099187.

Citing Articles

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.

Amati F, Stainer A, Polelli V, Mantero M, Gramegna A, Blasi F Int J Mol Sci. 2023; 24(9).

PMID: 37175556 PMC: 10178294. DOI: 10.3390/ijms24097849.

References

Traila D, Oancea C, Tudorache E, Mladinescu O, Timar B, Tudorache V . Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias. J Int Med Res. 2017; 46(1):448-456. PMC: 6011274. DOI: 10.1177/0300060517719767. View

Guler S, Ellison K, Algamdi M, Collard H, Ryerson C . Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2018; 15(7):854-863. DOI: 10.1513/AnnalsATS.201801-067OC. View

Chaudhuri N, Spencer L, Greaves M, Bishop P, Chaturvedi A, Leonard C . A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre. J Clin Med. 2016; 5(8). PMC: 4999786. DOI: 10.3390/jcm5080066. View

Cherchi R, Grimaldi G, Pinna-Susnik M, Riva L, Sarais S, Santoru M . Retrospective outcomes analysis of 99 consecutive uniportal awake lung biopsies: a real standard of care?. J Thorac Dis. 2020; 12(9):4717-4730. PMC: 7578489. DOI: 10.21037/jtd-20-1551. View

Krauss E, El-Guelai M, Pons-Kuehnemann J, Dartsch R, Tello S, Korfei M . Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg). J Clin Med. 2020; 9(8). PMC: 7464480. DOI: 10.3390/jcm9082499. View

Fang C, Huang H, Guo J, Ferianc M, Xu Z . Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice. PLoS One. 2020; 15(1):e0228390. PMC: 6992179. DOI: 10.1371/journal.pone.0228390. View

Cottin V, Wells A . Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category?. Eur Respir J. 2013; 42(3):576-9. DOI: 10.1183/09031936.00107713. View

Enomoto N, Naoi H, Aono Y, Katsumata M, Horiike Y, Yasui H . Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2020; 14:1753466620935774. PMC: 7328360. DOI: 10.1177/1753466620935774. View

Maldonado F, Danoff S, Wells A, Colby T, Ryu J, Liberman M . Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: CHEST Guideline and Expert Panel Report. Chest. 2019; 157(4):1030-1042. DOI: 10.1016/j.chest.2019.10.048. View

10.

Suzuki A, Kondoh Y, Brown K, Johkoh T, Kataoka K, Fukuoka J . Acute exacerbations of fibrotic interstitial lung diseases. Respirology. 2019; 25(5):525-534. DOI: 10.1111/resp.13682. View

11.

Flaherty K, Wells A, Cottin V, Devaraj A, Walsh S, Inoue Y . Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18):1718-1727. DOI: 10.1056/NEJMoa1908681. View

12.

Maher T, Corte T, Fischer A, Kreuter M, Lederer D, Molina-Molina M . Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respir Res. 2018; 5(1):e000289. PMC: 6135451. DOI: 10.1136/bmjresp-2018-000289. View

13.

Davidsen J, Raadal Skov I, Louw I, Laursen C . Implementation of transbronchial lung cryobiopsy in a tertiary referral center for interstitial lung diseases: a cohort study on diagnostic yield, complications, and learning curves. BMC Pulm Med. 2021; 21(1):67. PMC: 7908747. DOI: 10.1186/s12890-021-01438-1. View

14.

Ryerson C, Collard H . Update on the diagnosis and classification of ILD. Curr Opin Pulm Med. 2013; 19(5):453-9. DOI: 10.1097/MCP.0b013e328363f48d. View

15.

Wells A . "Any fool can make a rule and any fool will mind it". BMC Med. 2016; 14:23. PMC: 4748459. DOI: 10.1186/s12916-016-0562-1. View

16.

Maher T, Corte T, Fischer A, Kreuter M, Lederer D, Molina-Molina M . Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2019; 8(2):147-157. DOI: 10.1016/S2213-2600(19)30341-8. View

17.

Torrisi S, Kahn N, Walscher J, Polke M, Lee J, Molyneaux P . Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting. Front Pharmacol. 2022; 12:790204. PMC: 8718675. DOI: 10.3389/fphar.2021.790204. View

18.

Wong A, Lee T, Johannson K, Assayag D, Morisset J, Fell C . A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respir Res. 2020; 21(1):322. PMC: 7720501. DOI: 10.1186/s12931-020-01579-7. View

19.

Fisher J, Kolb M, Algamdi M, Morisset J, Johannson K, Shapera S . Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. BMC Pulm Med. 2019; 19(1):223. PMC: 6880596. DOI: 10.1186/s12890-019-0986-4. View

20.

Wells A, Flaherty K, Brown K, Inoue Y, Devaraj A, Richeldi L . Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020; 8(5):453-460. DOI: 10.1016/S2213-2600(20)30036-9. View